Alexion Pharmaceuticals

Alexion Pharmaceuticals — A to Z Product Catalog

Kanuma®
• Generic: Sebelipase alfa (enzyme replacement therapy)
• Indication: Lysosomal acid lipase deficiency (LAL-D)
• Dose/Form: Intravenous infusion (20 mg/10 mL formulation)

Koselugo®
• Generic: Selumetinib (MEK inhibitor)
• Indication: Neurofibromatosis type 1–associated plexiform neurofibromas (PNF) in children
• Dose/Form: Oral capsules (10 mg and 25 mg strengths)

Soliris®
• Generic: Eculizumab (monoclonal antibody complement C5 inhibitor)
• Indications: Paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD)
• Dose/Form: Intravenous infusion

Strensiq®
• Generic: Asfotase alfa (recombinant enzyme replacement)
• Indication: Perinatal-, infantile-, and juvenile-onset hypophosphatasia
• Dose/Form: Subcutaneous injection

Ultomiris®
• Generic: Ravulizumab-cwvz (long-acting complement C5 inhibitor)
• Indications: PNH, aHUS, generalized myasthenia gravis (gMG), NMOSD
• Dose/Form: Intravenous infusion (weight-based maintenance dosing every 4–8 weeks)

Voydeya®
• Generic: Danicopan (oral complement inhibitor)
• Indication: Add-on therapy for extravascular hemolysis in PNH, used with Soliris or Ultomiris
• Dose/Form: Oral tablets; typically 150 mg three times daily (up to 200 mg TID if needed)